Gastric response to metiamide.
Metiamide greatly reduced pentagastrin-stimulated and overnight secretion of acid and pepsin in 11 patients with duodenal ulcer and virtually abolished gastric secretion in three patients with gastric ulcer. The drug was equally effective when infused intravenously or intraduodenally. A therapeutic trial of Metiamide is warranted in diseases caused or aggravated by excess gastric secretion of acid and pepsin.
D001285:Atropine / Q000494:pharmacology; D003864:Depression, Chemical; D004381:Duodenal Ulcer / Q000188:drug therapy; D004386:Duodenum; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D010418:Pentagastrin / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism*; D010477:Perfusion; D012636:Secretory Rate / Q000187:drug effects; D013276:Stomach Ulcer / Q000188:drug therapy; D013890:Thiourea / Q000494:pharmacology* / Q000627:therapeutic use
D001285:Atropine; D010434:Pepsin A; D010418:Pentagastrin; D013890:Thiourea